Tesofensine is a small molecule rather than a peptide. Danuglipron is a copy of the gut hormone GLP-1.
They are aimed at different things: Tesofensine at weight loss; Danuglipron at weight loss (oral).
| Comparison | Tesofensine NS2330 | Danuglipron PF-06882961 |
|---|---|---|
| How it works | How it works Tesofensine is a stimulant-class small molecule, not a peptide. It was originally developed for Parkinson's disease, and the weight loss was noticed as a side effect. | How it works Danuglipron was an attempt at an oral GLP-1 pill using a small molecule rather than a peptide. Development stopped. |
| What it is | An experimental appetite-suppressing pill with strong weight-loss numbers. | An experimental weight-loss pill whose development was stopped over a liver-injury signal. |
| Status | In trialsInvestigational | In trialsInvestigational |
| Typical dose | 0.25–0.5 mg per day | 40–200 mg per dose |
| How often | Daily | Daily |
| Dose comes from | Published human study | Discontinued programme |
| Cycled? | Continuous daily dosing, studied to 24 weeks Published human study | No schedule. Development stopped in April 2025 Discontinued programme |
| What it does | ||
| Drug class | Triple reuptake inhibitor (not a peptide) | Oral GLP-1 (small molecule) |
| Used for | An experimental appetite-suppressing pill with strong weight-loss numbers. | An experimental appetite-lowering pill for weight loss, no needles. It is in testing. |
| Receptors hit | — | GLP-1 |
| Numbers | ||
| Full dose line | 0.25 up to 0.5 mg per day | 40 up to 200 mg per dose |
| Why that cycle | Given daily without breaks in the trials. The phase 2 study ran 24 weeks at up to 1 mg daily, with an extension to 48 weeks. No cycling was used or tested. | Pfizer ended the programme after a case of possible drug-induced liver injury, following the same fate as its sister compound the year before. Nothing about its dosing is worth planning around. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | Not disclosed | Not disclosed |
| Common vial | — | — |
| Before you start | ||
| Route | By mouth (oral) | By mouth (oral) |
| Do not use if | Uncontrolled high blood pressure Heart rhythm problems A history of psychiatric conditions Pregnancy | Development has stopped, so it is not available and no prescriber is assessing anyone for it |
What separates them
Proof behind the dose. Tesofensine has a dose from a published human study. Danuglipron has a dose from a programme that was stopped.
What doesn't differ: They are both taken the same way (by mouth) and on the same schedule (daily). Neither has a measured effect size from a published trial, so there is no number to rank them on.
What people actually report
Tesofensine
- It acts like a stimulant and can raise heart rate and blood pressure, so it carries more heart-related risk than other options.
- It is not approved, and not a peptide.
- A racing or pounding heartbeat
- Severe agitation, panic, or a marked change in mood
Danuglipron
- Stomach side effects.
- It is not approved, and it is a pill rather than a peptide.
- Yellowing of the skin or eyes, dark urine, or severe unexplained tiredness, which can signal liver injury
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.